The objective of the Indiana ACTU is to support and enhance the AIDS Clinical Trial Group in its efforts to develop and evaluate new and better modalities for the therapy of people with HIV infection. In this application we propose to continue our present ACTU at the Indiana University Hospitals and to add a subunit at Methodist Hospital in Indianapolis. The focus of our unit will be enrollment of patients in high priority protocols and, through an aggressive outreach program, enhanced enrollment of persons with HIV infection previously under-represented in clinical trials. Our unit will continue to contribute scientifically, especially in the area of treatment of opportunistic infections such as pneumocystis and histoplasmosis. In addition, we have added resources which will allow us to participate more fully in protocols directed at opportunistic malignancies and AIDS dementia, and allow us to continue to provide high quality data at a relatively low cost. In addition t the clinical trials unit, we are requesting support for a protocol mandated pharmacology core and for developmental research in the following areas: (1) Pharmacology; (2) Immunology; (3) Pneumocystis pneumonia; (4) Anti- fungal therapy. The developmental research in pharmacology will focus on assays for drugs used in HIV infection, on pharmacokinetics, and on drug interactions. The immunology research will focus on surrogate markers of disease progression which can be analyzed by flow cytometry. Developmental research in pneumocystis will focus on strain and antibiotic susceptibility differences in isolates from patients with recurrent episodes of pneumocystis. The focus of the anti-fungal project will be provision of a centralized laboratory which can perform specialized anti-fungal testing required to support clinical trials. It will serve as repository for organisms and specimens and develop and provide antigen detection for histoplasmosis, as well as other fungi.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
2U01AI025859-06
Application #
3546814
Study Section
Special Emphasis Panel (SRC (75))
Project Start
1987-09-30
Project End
1996-01-31
Budget Start
1992-04-01
Budget End
1993-01-31
Support Year
6
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Type
Schools of Medicine
DUNS #
005436803
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9

Showing the most recent 10 out of 181 publications